3rd World ADC Asia 2020
December 7 - 9, 2020 - JPHanson Wade
adc@hansonwade.com
Phone:+14157353289
World ADC Asia prides itself in being the only dedicated conference that unites the leaders in the antibody-drug conjugate field to identify and discuss the critical factors that will influence the next 12 months of your ADC development. This conference was designed with the leaders from, Daiichi Sankyo, Eisai, Shanghai Miracogen and Immunowork, and it has an agenda that addresses the biggest challenges, latest data, science and lessons learned from the last year of ADC drug development. Across 3 days, with 100+ ADC experts, this comprehensive antibody-drug conjugate conference will enable you to propel your ADC pipeline into clinical development. Some of the highlights from the 2020 meeting include exploring targets beyond HER-2; confidently meeting Chinese NMPA regulatory requirements to successfully translate into the clinic and effectively scaling up your manufacturing processes for clinical development. World ADC Asia not only delves into general antibody-drug conjugate challenges, it also focuses on challenges and opportunities specific to development within Asia. With partnerships being a huge factor in providing momentum of ADC drug development in Asia, this is your perfect opportunity to gain critical insight and valuable partnerships to accelerate the development of your ADC drug pipeline. Don't miss your opportunity to: * Hear the rationale for submitting INDs in different countries; how to leverage the strength of Asia and US/Europe with the NMPA, BlissBio and Shanghai Miracogen * Form lasting connections by engaging directly with 100+ attendees from the leading companies actively developing ADCs in Asia, such as Daiichi Sankyo, Bio-Thera, Sumitomo Dainippon Pharma Co, Seattle Genetics and Mersana * Learn from the leading Chinese biotech's who have recently submitted INDs or entered the clinic including Shanghai Miracogen, Blissbio and Genequantum